Group 1 - The company reported revenue of $12.3 million for Q1 2025, reflecting a 15% growth compared to the same quarter last year, aligning with preliminary results shared earlier [5] - The company aims to establish Barostim as the standard of care in its field [5] Group 2 - The earnings call included forward-looking statements regarding financial guidance, which are subject to change based on various risks and uncertainties [4] - The call featured participation from key executives, including the President and CEO, Kevin Hykes, and CFO, Jared Oasheim [3]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40545 CVRx, Inc. (Exact name of registrant as specified in its charter) Delaware 41-1983744 (State or other j ...

CVRx (CVRX) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.56. This compares to loss of $1.04 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 5.36%. A quarter ago, it was expected that this medical device company would post a loss of $0.37 per share when it actually produced a loss of $0.43, delivering a surprise of -16.22%.Over the last four quarters, the company has surp ...

CVRx (CVRX) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Speaker0 Standby, your program is about to begin. Good day, everyone, and welcome to today's CVRx Q1 twenty twenty five Earnings Call. At this time, all participants are in a listen only mode. Later, you will have the opportunity to ask questions during the question and answer session. Please note this call is being recorded. I will be standing by if you should need any assistance. It is now my pleasure to turn the conference over to Mike Valley fro ...

Financial Results - CVRx, Inc. announced preliminary financial results for Q1 2025, ending March 31, 2025[5] - A press release detailing the financial results was issued on April 7, 2025[5] Company Classification - The company is classified as an emerging growth company under the Securities Act of 1933[4]

MINNEAPOLIS, May 08, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the first quarter of 2025. Recent Highlights Total revenue for the first quarter 2025 was $12.3 million, an increase of 15% over the prior year quarterU.S. Heart Failure (HF) revenue for the firs ...

The market expects CVRx (CVRX) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on May 8, 2025, might help the stock move higher if these key numbers are better than ...

MINNEAPOLIS, April 24, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today announced that it plans to release first quarter 2025 financial and operating results after market close on Thursday, May 8, 2025. The Company will host a conference call to review its results at 4:30pm Eastern Time the same day. A live webcast of the investor conference call will be available online at the investor relations page of the Company’s website at ir.cvrx.com. To li ...

Core Insights - CVRx Inc's stock has experienced a significant decline of 60% since the last analysis, indicating a potential overvaluation in the market [1]. Company Analysis - The previous thesis suggested that CVRx Inc's stock was overpriced and that its top-line growth was already factored into the stock price [1]. - The company is being observed for potential investment opportunities as the stock price has dropped dramatically, which may present a more attractive entry point for investors [1]. Investor Perspective - The analysis reflects a value investing approach, focusing on identifying bargains in the market, particularly in emerging markets [1]. - The investor emphasizes an owner-mindset and a willingness to go against prevailing market trends, suggesting a long-term investment strategy [1].

Core Viewpoint - CVRx, Inc. anticipates first quarter 2025 revenue of approximately $12.3 million, reflecting a growth of about 15% compared to the same period in 2024, despite falling short of expectations due to seasonal factors and the integration of new sales representatives [1][2][3]. Financial Performance - Expected total revenue for Q1 2025 is approximately $12.3 million, up from $10.8 million in Q1 2024, indicating a 15% increase [3]. - Q1 2024 revenue breakdown includes approximately $11.2 million from the U.S. and $1.1 million from Europe [3]. Sales and Market Strategy - The company is focused on enhancing Barostim adoption through a strengthened sales organization, having recruited new high-quality sales representatives [2]. - The first quarter of 2025 experienced seasonal softness, affecting revenue as patients scheduled procedures around insurance coverage and deductibles [2]. Operational Metrics - As of March 31, 2025, CVRx had 227 active implanting centers in the U.S., an increase from 223 as of December 31, 2024 [4]. - The number of sales territories in the U.S. decreased by 3 to a total of 45 during the first quarter of 2025 [4]. Cash Position - As of March 31, 2025, the company reported cash and cash equivalents of $102.7 million [4]. - During the first quarter, CVRx issued 543,462 shares of common stock for gross proceeds of $9.5 million under its at-the-market offering [4]. Upcoming Events - The company plans to release its full financial and operating results for Q1 2025 after market close on May 8, 2025, followed by a conference call at 4:30 p.m. Eastern Time [5][6].